Weekly Isotretinoin vs Tetracycline for Moderate Acne

Launched by MEDICAL UNIVERSITY OF SOUTH CAROLINA · Jan 16, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to treat moderate acne, which is a common skin condition that can affect both teenagers and adults. Researchers are comparing a weekly dose of Isotretinoin, a medication known for its effectiveness in treating acne, to a daily antibiotic called Doxycycline. The goal is to see if the weekly Isotretinoin can help improve acne without the side effects that can come with other treatments, especially since long-term antibiotic use can lead to other health issues. This study is currently looking for participants aged 12 and older who have moderate acne but who are not on certain medications that could interfere with the study.

If you decide to participate, you will be randomly assigned to either the Isotretinoin or the Doxycycline group for four months. Throughout the trial, researchers will monitor your progress, side effects, and overall satisfaction with the treatment. It's important to know that this trial has specific requirements, such as not having certain medical conditions or being on specific medications. This research could potentially lead to a new and safer option for treating moderate acne, helping many people find relief from their skin issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Male and Female patients, 12 years and older with a diagnosis of Moderate Acne Vulgaris
• Exclusion Criteria:
• • Patients who are at baseline on long-term Tetracycline antibiotics, long-term Trimethoprim-Sulfamethoxazole, or on Spironolactone for any reason
• • Patients who have taken Isotretinoin in the past 6 months
• • Patients with hypersensitivity to Isotretinoin or to any of its components
• • Females who are pregnant, likely to become pregnant, or will be breast-feeding during the study period
• • Patients with a history of major depression, mania, or psychosis with an active episode during the past year including current psychotic symptoms and/or current suicidal ideation
• • Adult patients with cognitive impairment
• • Patients with baseline kidney or liver disease
• • Patients with baseline hypertriglyceridemia
• • Patients with history of or current pseudotumor cerebri
• • Patients with any clinically significant unstable medical condition which could pose a risk to the safety of the patient
• • Inability or unwillingness of subject or legal guardian/representative to give informed consent